Back to Search Start Over

Concurrent administration of adjuvant chemotherapy and radiotherapy after breast-conserving surgery enhances late toxicities: long-term results of the ARCOSEIN multicenter randomized study

Authors :
Jean-François Bosset
Noel Breteau
Olivier Le Floch
Alain Fourquet
Gilles Body
Pascal Garaud
David Azria
Gilles Calais
Daniel Serin
Alain Toledano
Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO)
Université de Franche-Comté (UFC)
Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)
Institut de recherche en cancérologie de Montpellier (IRCM - U896 Inserm - UM1)
CRLCC Val d'Aurelle - Paul Lamarque-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Montpellier 1 (UM1)
CRLC Val d'Aurelle-Paul Lamarque
CRLCC Val d'Aurelle - Paul Lamarque
Hôpital Bretonneau
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bretonneau
Imagerie fonctionnelle (IF)
Institut National de la Recherche Agronomique (INRA)-EFS-Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO )
Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ) -Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon )
Institut de recherche en cancérologie de Montpellier ( IRCM )
Université Montpellier 1 ( UM1 ) -CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Montpellier ( UM )
Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Bretonneau
Imagerie fonctionnelle ( IF )
Institut National de la Recherche Agronomique ( INRA ) -EFS-CHRU Tours-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS )
Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Université de Franche-Comté (UFC)
Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Bretonneau
Source :
International Journal of Radiation Oncology-Biology-Physics, International Journal of Radiation Oncology-Biology-Physics, Elsevier, 2006, 65 (2), pp.324-32. ⟨10.1016/j.ijrobp.2005.12.020⟩, International Journal of Radiation Oncology*Biology*Physics / International Journal of Radiation Oncology Biology Physics; International Journal of Radiation Oncology Biology & Physics, International Journal of Radiation Oncology*Biology*Physics / International Journal of Radiation Oncology Biology Physics; International Journal of Radiation Oncology Biology & Physics, undefined or unknown publisher, 2006, 65 (2), pp.324-32. 〈10.1016/j.ijrobp.2005.12.020〉
Publication Year :
2006
Publisher :
HAL CCSD, 2006.

Abstract

International audience; PURPOSE: In 1996, a multicenter randomized study was initiated that compared sequential vs. concurrent adjuvant chemotherapy (CT) with radiation therapy (RT) after breast-conserving surgery (ARCOSEIN study). After a median follow-up of 6.7 years (range, 4.3-9 years), we decided to prospectively evaluate the late effects of these 2 strategies. METHODS AND MATERIALS: A total of 297 patients from the 5 larger participating institutions were asked to report for a follow-up examination. Seventy-two percent (214 patients) were eligible for evaluation of late toxicity. After breast-conserving surgery, patients were treated either with sequential treatment with CT first followed by RT (Arm A) or CT administered concurrently with RT (Arm B). In all patients, CT regimen consisted of mitoxantrone (12 mg/m2), 5-FU (500 mg/m2), and cyclophosphamide (500 mg/m2), 6 cycles (Day 1 to Day 21). Conventional RT was delivered to the whole breast by administration of a 2 Gy per fraction protocol to a total dose of 50 Gy (+/- boost to the primary tumor bed). The assessment of toxicity was blinded to treatment and was graded by the radiation oncologist, according to the LENT/SOMA scale. Skin pigmentation was also evaluated according to a personal 5-points scoring system (excellent, good, moderate, poor, very poor). RESULTS: Among the 214 evaluable patients, 107 were treated in each arm. The 2 populations were homogeneous for patient, tumor, and treatment characteristics. Subcutaneous fibrosis (SF), telangectasia (T), skin pigmentation (SP), and breast atrophy (BA) were significantly increased in Arm B. No statistical difference was observed between the 2 arms of the study concerning Grade 2 or higher pain, breast edema, or lymphedema. No deaths were caused by late toxicity. CONCLUSION: After breast-conserving surgery, the concurrent use of CT with RT is significantly associated with an increase incidence of Grade 2 or greater late side effects.

Subjects

Subjects :
Cancer Research
MESH: Combined Modality Therapy
MESH : Antineoplastic Combined Chemotherapy Protocols
medicine.medical_treatment
MESH : Aged
MESH : Prospective Studies
Skin Pigmentation
Segmental
MESH : Breast Neoplasms
Mastectomy, Segmental
[ SDV.CAN ] Life Sciences [q-bio]/Cancer
030218 nuclear medicine & medical imaging
0302 clinical medicine
Antineoplastic Combined Chemotherapy Protocols
Breast-conserving surgery
MESH : Female
Prospective Studies
MESH: Radiotherapy Dosage
MESH : Cyclophosphamide
Radiation oncologist
Mastectomy
Adjuvant
MESH: Aged
Radiation
MESH: Middle Aged
MESH : Neoplasm Recurrence, Local
MESH : Radiotherapy Dosage
MESH : Chemotherapy, Adjuvant
Radiotherapy Dosage
MESH : Adult
Middle Aged
Combined Modality Therapy
3. Good health
MESH: Antineoplastic Combined Chemotherapy Protocols
Oncology
Local
Chemotherapy, Adjuvant
MESH: Chemotherapy, Adjuvant
030220 oncology & carcinogenesis
MESH : Fluorouracil
Female
MESH: Skin Pigmentation
Fluorouracil
MESH: Mitoxantrone
MESH: Neoplasm Recurrence, Local
medicine.drug
Adult
medicine.medical_specialty
Cyclophosphamide
Urology
Breast Neoplasms
[SDV.CAN]Life Sciences [q-bio]/Cancer
03 medical and health sciences
Breast cancer
medicine
Chemotherapy
Humans
MESH : Middle Aged
Radiology, Nuclear Medicine and imaging
MESH: Mastectomy, Segmental
MESH : Mastectomy, Segmental
Subcutaneous fibrosis
Aged
MESH: Humans
business.industry
MESH : Humans
MESH: Cyclophosphamide
MESH: Adult
medicine.disease
MESH: Prospective Studies
Surgery
Radiation therapy
Regimen
Neoplasm Recurrence
MESH : Mitoxantrone
Neoplasm Recurrence, Local
MESH : Skin Pigmentation
Mitoxantrone
MESH : Combined Modality Therapy
business
MESH: Female
MESH: Fluorouracil
MESH: Breast Neoplasms

Details

Language :
English
ISSN :
03603016
Database :
OpenAIRE
Journal :
International Journal of Radiation Oncology-Biology-Physics, International Journal of Radiation Oncology-Biology-Physics, Elsevier, 2006, 65 (2), pp.324-32. ⟨10.1016/j.ijrobp.2005.12.020⟩, International Journal of Radiation Oncology*Biology*Physics / International Journal of Radiation Oncology Biology Physics; International Journal of Radiation Oncology Biology & Physics, International Journal of Radiation Oncology*Biology*Physics / International Journal of Radiation Oncology Biology Physics; International Journal of Radiation Oncology Biology & Physics, undefined or unknown publisher, 2006, 65 (2), pp.324-32. 〈10.1016/j.ijrobp.2005.12.020〉
Accession number :
edsair.doi.dedup.....25be0419cc14b24a5b4ce81014704436